- Home
- ASM vs PBYI Comparison
ASM vs PBYI Comparison
Compare ASM & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASM
- PBYI
- Stock Information
- Founded
- ASM 1968
- PBYI 2010
- Country
- ASM Canada
- PBYI United States
- Employees
- ASM N/A
- PBYI N/A
- Industry
- ASM Metal Mining
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ASM Basic Materials
- PBYI Health Care
- Exchange
- ASM Nasdaq
- PBYI Nasdaq
- Market Cap
- ASM 146.2M
- PBYI 153.2M
- IPO Year
- ASM N/A
- PBYI N/A
- Fundamental
- Price
- ASM $1.12
- PBYI $2.95
- Analyst Decision
- ASM Strong Buy
- PBYI Strong Buy
- Analyst Count
- ASM 2
- PBYI 1
- Target Price
- ASM $1.80
- PBYI $7.00
- AVG Volume (30 Days)
- ASM 1.2M
- PBYI 808.8K
- Earning Date
- ASM 11-12-2024
- PBYI 02-27-2025
- Dividend Yield
- ASM N/A
- PBYI N/A
- EPS Growth
- ASM 144.19
- PBYI 492.79
- EPS
- ASM 0.02
- PBYI 0.47
- Revenue
- ASM $54,326,000.00
- PBYI $243,569,000.00
- Revenue This Year
- ASM $40.31
- PBYI N/A
- Revenue Next Year
- ASM $33.83
- PBYI N/A
- P/E Ratio
- ASM $43.41
- PBYI $6.41
- Revenue Growth
- ASM 18.08
- PBYI 6.30
- 52 Week Low
- ASM $0.44
- PBYI $2.23
- 52 Week High
- ASM $1.56
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- ASM 62.48
- PBYI 46.46
- Support Level
- ASM $1.06
- PBYI $2.92
- Resistance Level
- ASM $1.21
- PBYI $4.06
- Average True Range (ATR)
- ASM 0.06
- PBYI 0.24
- MACD
- ASM 0.03
- PBYI -0.04
- Stochastic Oscillator
- ASM 78.57
- PBYI 5.70
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.